BLTE
Belite BioDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-22
Current thesis
A favorable DRAGON readout or a strategic partnership materially re-rates the stock toward the analyst high (200.0), improving commercial visibility and justifying upside beyond the modest base.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -10.6.
What can break
Insufficient cash / dilutive financing
Momentum
33
Value
41
Sentiment
50
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $165.29 · Bull $200.00 · Bear $85.00
Data freshness
Prices
As of 2026-07-22
Fundamentals
As of 2026-07-22 • Vendor: Data Vendor v1
Scores
As of 2026-07-22 • Model: HYBRID_IC_RP
AI Memo
As of 2026-01-17 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-22
Investment thesis
As of 2026-07-22
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $210.50
Why
Momentum33 · Δ7d +27.5
Value41 · Δ7d -0.0
Sentiment50 · Δ7d -10.6
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Sentiment · See AI snapshot
Momentum
33
26% active weight
Current posture
7d trendImproving
Δ7d
+27.5
Δ21d
+13.7
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-0.1
Sentiment
50
34% active weight
Current posture
7d trendSoftening
Δ7d
-10.6
Δ21d
-6.2
Why this grade
Composite grade D. Momentum 32.5 / Value 41.1 / Sentiment 49.7
Fundamentals (TTM)As of 2026-07-22
Fundamentals (TTM)
As of 2026-07-22
Market Cap
$6.3B
Beta
-1.46
Shares Out
40.09M
P/E (TTM) · Derived
-67.9
P/S (TTM)
-
P/FCF (TTM)
-
Rev YoY
-
EPS YoY
+51.8%
Gross Margin
-
Op Margin
-
Net Debt
-$491.99M
Current Ratio
50.02
As of 2026-07-22 • Updated nightlySource: Internal modelMethodology